Latest News
Pfizer starts patient enrolment in Phase II clinical trial of PF-06252616
19 December 2014 - Pfizer, a global biopharmaceutical company, has commenced patient enrolment in a multicentre Phase II clinical trial of PF-06252616, an experimental, infused, anti-myostatin monoclonal antibody, to treat Duchenne muscular dystrophy, it was reported yesterday.

The trial is aimed at assessing the safety, tolerability and efficacy of PF-06252616 in boys aged six to less than ten years old, diagnosed with Duchenne muscular dystrophy regardless of genotype.

Pfizer Rare Disease Research Unit senior vice-president and chief scientific officer, Kevin Lee, said, 'Duchenne muscular dystrophy is a devastating and debilitating disease impacting approximately 1 in 3,500 male births worldwide with no current treatment options. We are pleased to be taking this important next step in the development of PF-06252616 as an investigational therapy for DMD in the hopes of potentially bringing a much-needed therapy to individuals and families with this devastating disease.'

Login
Username:

Password: